Stifel raised the firm’s price target on NervGen Pharma (NGENF) to C$5 from C$4.50 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGENF:
- NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
- NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
- NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
- NervGen Pharma Awards Stock Options to Directors and Employees
- NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development